117 related articles for article (PubMed ID: 19288003)
1. Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome.
Telang N; Katdare M
Oncol Rep; 2009 Apr; 21(4):1017-21. PubMed ID: 19288003
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive agents inhibit aberrant proliferation of the aneuploid phenotype in a colon epithelial cell line established from Apc 1638N [+/-] mouse.
Katdare M; Kopelovich L; Telang N
Ann N Y Acad Sci; 2001 Dec; 952():169-74. PubMed ID: 11795437
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer.
Telang N; Katdare M
Oncol Rep; 2007 Apr; 17(4):909-14. PubMed ID: 17342335
[TBL] [Abstract][Full Text] [Related]
4. Cell culture model for colon cancer prevention and therapy: an alternative approach to animal experimentation.
Telang N; Katdare M
ALTEX; 2007; 24(1):16-21. PubMed ID: 17361317
[TBL] [Abstract][Full Text] [Related]
5. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of chemopreventive agents for growth inhibition of Apc [+/-] 1638NCOL colonic epithelial cells.
Katdare M; Kopelovich L; Telang N
Int J Mol Med; 2002 Oct; 10(4):427-32. PubMed ID: 12239589
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
9. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.
Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM
Carcinogenesis; 1998 Jan; 19(1):87-91. PubMed ID: 9472698
[TBL] [Abstract][Full Text] [Related]
10. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
Telang N; Katdare M
Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate.
Rao CV; Cooma I; Rodriguez JG; Simi B; El-Bayoumy K; Reddy BS
Carcinogenesis; 2000 Apr; 21(4):617-21. PubMed ID: 10753194
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of familial adenomatous polyposis by bromo-noscapine (EM011) in the Apc(Min/+) mouse model.
Li S; Ghaleb AM; He J; Bughani U; Bialkowska AB; Yang VW; Joshi HC
Int J Cancer; 2012 Sep; 131(6):1435-44. PubMed ID: 22052467
[TBL] [Abstract][Full Text] [Related]
13. Stem cell models for genetically predisposed colon cancer.
Telang N
Oncol Lett; 2020 Nov; 20(5):138. PubMed ID: 32934706
[TBL] [Abstract][Full Text] [Related]
14. A Patient With Desmoid Tumors and Familial FAP Having Frame Shift Mutation of the APC Gene.
Sadighi S; Ghaffari-Moghaddam M; Saffari M; Mohagheghi MA; Shirkoohi R
Acta Med Iran; 2017 Feb; 55(2):134-138. PubMed ID: 28282712
[TBL] [Abstract][Full Text] [Related]
15. Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models.
Gerner EW
Biochem Soc Trans; 2007 Apr; 35(Pt 2):322-5. PubMed ID: 17371270
[TBL] [Abstract][Full Text] [Related]
16. Sulindac in familial adenomatous polyposis.
Levy R
N Engl J Med; 2002 Aug; 347(8):615. PubMed ID: 12192027
[No Abstract] [Full Text] [Related]
17. Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Uckun FM; Erbeck D; Qazi S; Venkatachalam T; Tibbles HE; Vassilev A
Arzneimittelforschung; 2007; 57(6):320-9. PubMed ID: 17688077
[TBL] [Abstract][Full Text] [Related]
18. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.
Erdman SH; Ignatenko NA; Powell MB; Blohm-Mangone KA; Holubec H; Guillén-Rodriguez JM; Gerner EW
Carcinogenesis; 1999 Sep; 20(9):1709-13. PubMed ID: 10469614
[TBL] [Abstract][Full Text] [Related]
19. 3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin.
Bhatnagar N; Li X; Chen Y; Zhou X; Garrett SH; Guo B
Cancer Prev Res (Phila); 2009 Jun; 2(6):581-9. PubMed ID: 19470789
[TBL] [Abstract][Full Text] [Related]
20. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
